Navigation Links
Aethlon Medical Initiates Swine Flu Testing Program

SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today disclosed that researchers have initiated testing of its Hemopurifier(R) as a candidate treatment against the H1N1 Swine Flu Virus. The Hemopurifier(R) is the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The device has been designed to enhance the benefit of antiviral drug regimens, and it provides a therapeutic option against infectious viruses not addressed by drug and vaccine therapies.


The studies, which are testing the effectiveness of the Hemopurifier(R) to capture the H1N1 virus, are being conducted at laboratories approved by the United States Department of Health and Human Services to house and conduct research on pandemic strains of H1N1 virus. The Hemopurifier(R) has previously proven effective in capturing the reconstructed Spanish flu of 1918 virus (1918rv) and the H5N1 avian influenza virus (Bird Flu). The Hemopurifier(R) represents a promising strategy to clear infectious H1N1 swine flu from the bloodstream as the device selectively captures influenza viruses by hemagglutinin (HA) and neuraminidase (NA) glycoproteins that coat the virus, even when influenza mutates to be resistant against drug and vaccine therapies.

The World Health Organization (WHO) now projects that two billion people, or one third of the world's population, will become infected by the virus before the end of the pandemic. Last week, WHO also reported that 1,154 swine flu victims have died since the virus emerged in April, including 338 deaths reported in the prior week alone. Additionally, six patients have recently been identified with viral strains resistant to treatment with Tamiflu, the stockpiled antiviral treatment for pandemic forms of influenza.

"Beyond surging death tolls and reports of drug resistance, the potential for the swine flu virus to mutate into a virulent and lethal form seems increasingly possible over the course of the two billion infections projected by WHO," stated Aethlon Chairman and CEO, Jim Joyce. "While our primary focus remains the treatment of Hepatitis-C virus (HCV), it is now appropriate and important that we take advantage of the opportunity to validate the capability of our Hemopurifier(R) against infectious H1N1 Swine flu virus," concluded Joyce.

Since the beginning of 2009, the Hemopurifier(R) has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. As a result, Aethlon believes the Hemopurifier(R) is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies. Such data further reinforces the position of the Hemopurifier(R) as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Should H1N1 Swine Flu evolve to be highly virulent and resistant to treatment stockpiles, the Hemopurifier(R) is positioned to become a first-line treatment countermeasure to strengthen the clinical benefit of both established and candidate drug treatments.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at


    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
3. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
6. Aethlon Medical Announces U.S. Army Agreement
7. MSU engineering team designs innovative medical device
8. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
10. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
11. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology: